Abstract
Introduction: Renal cell carcinoma (RCC) has varied presentations and outcomes. TNM Stage, pathological features and performance status are the established factors prognosticating the disease. Recently, role of thromobocytosis has been evaluated as simple, cost effective and accurate prognostic marker in RCC patients.
Objective: To study the effect of thromobocytosis in renal cell carcinoma on prognosis of disease.
Materials And Methods: A retrospective observational follow-up study of 142 patients with RCC from January 2007 to December 2017 was conducted at Institute of Nephrourology, Bengaluru (Karnataka). Platelet count more than 400000/mm3 was considered as thrombocytosis. The clinical parameters, tumour stage, grade, progression and survival of the disease were compared with respect to platelet count. Mean follow-up was 28 months (24-60 months). Patients time to disease progression and overall survival were studied with regard to thromobocytosis. Data was analysed using SPSS V26.0 using Chi square test, binary logistic and linear regression model and Kaplan Meir curve.
Results: Mean age was 54.59 years. Mean platelet count was 2, 45,292 /mm3 and mean tumour size was 7.67cm. Thromobocytosis correlates with total leucocyte count (p value <0.001), tumour necrosis (p value 0.04), lymph node invasion(p value 0.01), metastasis( p value 0.027), TNM stage(p value <0.001) and overall survival(p value <0.001). These patients also had poor histology and more lymphovascular invasion. On regression analysis only TNM stage correlates significantly (p value 0.01) with time to progression. Platelet count >400000/mm3 was associated with poorer survival outcomes with 5-year mortality rate of 38%.
Conclusion: Thrombocytosis in RCC is associated with advanced disease, poor histology and rapid disease progression. It is simple and easy tool for prognosticating RCC and predicting survival outcomes.

Key words: TNM stage, Renal Malignancy, followup, Platelet Count, Survival.